Pull to refresh
Logo
Daily Brief
Following Why Sign Up
Marc N. Casper

Marc N. Casper

Chairman and Chief Executive Officer, Thermo Fisher Scientific

Appears in 1 story

Notable Quotes

"Clario is an outstanding strategic fit for our company, enhancing our ability to enable faster, more informed drug development through differentiated technology and data intelligence solutions." — upon announcing the deal

"We've long admired Clario and this acquisition underscores our disciplined capital deployment strategy, which has an outstanding track record of creating shareholder value."

Stories

Thermo Fisher completes nearly $9 billion acquisition of clinical trial data company Clario

Money Moves

Leading post-acquisition integration

Thermo Fisher Scientific, one of the world's largest scientific instrumentation companies, closed its $8.875 billion cash purchase of Clario Holdings on March 24, 2026. Clario provides the digital tools that pharmaceutical companies use to collect patient data during clinical trials — technology that has contributed to roughly 70 percent of drugs approved by the Food and Drug Administration (FDA) over the past decade. The deal, first announced in October 2025, also includes up to $525 million in additional payments tied to Clario's near-term performance, bringing the total potential price to approximately $9.4 billion.

Updated Yesterday